Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally

Eur Respir J. 2022 Aug 25;60(2):2201227. doi: 10.1183/13993003.01227-2022. Print 2022 Aug.

Abstract

Global access to rifapentine is essential to implement the latest WHO recommendations on treatment of TB infection and disease. Measures to increase access to rifapentine include strengthening regulatory reliance practices. https://bit.ly/3xNDwID

Publication types

  • Letter
  • Comment

MeSH terms

  • Europe
  • Humans
  • Isoniazid
  • Rifampin / analogs & derivatives
  • Rifampin / therapeutic use
  • Tuberculosis* / drug therapy
  • Tuberculosis* / epidemiology
  • Tuberculosis* / prevention & control

Substances

  • Isoniazid
  • Rifampin
  • rifapentine